Caitong International Asset Management’s ADC Therapeutics ADCT Stock Holding History

Caitong International Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8	Buy	+2	New	+$8	﹤0.01%	2177

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caitong International Asset Management's ADCT Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 2 shares worth $8. The stake represents ﹤0.01% of the portfolio and ranks #2177 among its holdings.

118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Caitong International Asset Management held 2 shares of ADC Therapeutics worth $8 as of Q1 2026.
ADC Therapeutics was a new Caitong International Asset Management position in Q1 2026.
ADC Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2177 holding.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.